Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

NCT04739566 is registered in ClinicalTrials.gov with Saint Petersburg State University, Russia as lead sponsor.

NCT NCT04739566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)
Lead sponsor
Saint Petersburg State University, Russia
Phase
Phase 2
Overall status
Withdrawn
Start date
January 22, 2021
Completion date
December 22, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid gland anaplastic carcinoma